The specific and rapid assay of inhibin and its clinical applications

RIA中所用的抗Escherichia bin多克隆抗体与Escherichia bin A、Escherichia bin B和Escherichia bin α单体反应。我们的IR-Bin RIA系统比莫纳什RIA更准确地估计Bin B的量，并且在正常周期期间IR-Bin的模式反映Bin A和Bin B两者。通过改变缓冲液和碘化方法，提高了检测系统的灵敏度，最低检测浓度为0.1IU/ml。使用该测定系统，测量各种临床样品中的IR-β-D-半胱氨酸水平。颗粒细胞患者的血清IR-Rbbin水平反映了临床状况。在这些患者中，在肿瘤完全切除后，IR-121-bin水平下降到可检测的限度以下，并且在复发的情况下比其他肿瘤标记物更早地增加。在接受促性腺激素诱导排卵的女性中，表现为OHSS的患者中，IR-β-受体结合素的增加早于β-受体结合素A或β-受体结合素B。因此，有可能IR-β-受体结合蛋白是卵巢过度刺激的良好标志物。IR-BABIN低于60岁以上女性的敏感水平。为了确定IR-Risobin是否适合作为肿瘤标志物，我们正在对60岁以上妇女的大量样本进行研究。我们还开发了Risobin A免疫荧光测定法，并正在继续对妊娠期间Risobin A进行研究。所研制的抗人白蛋白B抗体不适用于免疫荧光分析。

The anti-inhibin polyclonal antibody used in our RIA reacts with inhibin A, inhibin B, and inhibin α-monomer. Our inhibin RIA system estimates the amount of inhibin B more accurately than Monash RIA and the pattern of IR-inhibin during normal cycle reflects both inhibin A and inhibin B. We improved the sensitivity of this assay system by changing the buffer and iodination methods and obtained the minimum detection level with 0.1 IU/ml. Using this assay system, IR-inhibin levels in various clinical samples were measured. Serum IR-inhibin levels of patients with granulosa cells reflect the clinical conditions. IR-inhibin levels dropped below the detectable limit after total removal of the tumor in these patients and increased earlier in the case of relapse than other tumor markers. IR-inhibin increased earlier than inhibin A or inhibin B in the patient who manifested OHSS among women undergoing ovulation induction by ganadotropins. Therefore there is the possibility that IR-inhibin is a good marker of hyperstimulation of the ovaries. IR-inhibin was below the sensitivity level among women over 60 years old. The study of a large number of samples from women over 60 years old is ongoing, in order to determine whether IR-inhibin is suitable as a tumor marker or not.We also developed inhibin A immunofluorometric assay and the study of inhibin A during pregnancy measured by this assay is continuing. The anti inhibin B antibody which was developed was not suitable for immunofluorometric assay.